Merrimack Pharmaceuticals Inc. (MACK) announced preclinical study results showing that the novel therapy MM-121 restores tumor sensitivity and delays the onset of resistance to the aromatase inhibitor, letrozole, in an ER+ breast cancer model.
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival. By inhibiting ErbB3 signaling, MM-121 was found to restore sensitivity, delay resistance and enhance the anti-tumor effect of letrozole as a combination therapy partner.
For comments and feedback: editorial@rttnews.com